Assays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84159
Title:
Assays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay.
Authors:
Turner, Suzanne D; Wijnhoven, S W; Tinwell, H; Lashford, Linda S; Rafferty, Joseph A; Ashby, J; Vrieling, H; Fairbairn, Leslie J
Abstract:
The topoisomerase II inhibitor etoposide is used routinely to treat a variety of cancers in patients of all ages. As a result of its extensive use in the clinic and its association with secondary malignancies it has become a compound of great interest with regard to its genotoxic activity in vivo. This paper describes a series of assays that were employed to determine the in vivo genotoxicity of etoposide in a murine model system. The alkaline comet assay detected DNA damage in the bone marrow mononuclear compartment over the dose range of 10--100mg/kg and was associated with a large and dose dependent rise in the proportion of cells with severely damaged DNA. In contrast, the bone marrow micronucleus assay was found to be sensitive to genotoxic damage between the doses of 0.1--1mg/kg without any corresponding increases in cytotoxicity. An increase in the mutant frequency was undetectable at the Hprt locus at administered doses of 1 and 10mg/kg of etoposide, however, an increase in the mutant frequency was seen at the Aprt locus at these doses. We conclude that the BMMN assay is a good short-term predictor of the clastogenicity of etoposide at doses that do not result in cytotoxic activity, giving an indication of potential mutagenic effects. Moreover, the detection of mutants at the Aprt locus gives an indication of the potential of etoposide to cause chromosomal mutations that may lead to secondary malignancy.
Affiliation:
Gene Therapy Group, Christie Hospital (NHS) Trust, Wilmslow Road, Manchester M20 4BX, UK. suzanne.turner@bbsrc.ac.uk
Citation:
Assays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay. 2001, 493 (1-2):139-47 Mutat. Res.
Journal:
Mutation Research
Issue Date:
27-Jun-2001
URI:
http://hdl.handle.net/10541/84159
PubMed ID:
11516723
Type:
Article
Language:
en
ISSN:
0027-5107
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorTurner, Suzanne Den
dc.contributor.authorWijnhoven, S Wen
dc.contributor.authorTinwell, Hen
dc.contributor.authorLashford, Linda Sen
dc.contributor.authorRafferty, Joseph Aen
dc.contributor.authorAshby, Jen
dc.contributor.authorVrieling, Hen
dc.contributor.authorFairbairn, Leslie Jen
dc.date.accessioned2009-10-13T10:40:41Z-
dc.date.available2009-10-13T10:40:41Z-
dc.date.issued2001-06-27-
dc.identifier.citationAssays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay. 2001, 493 (1-2):139-47 Mutat. Res.en
dc.identifier.issn0027-5107-
dc.identifier.pmid11516723-
dc.identifier.urihttp://hdl.handle.net/10541/84159-
dc.description.abstractThe topoisomerase II inhibitor etoposide is used routinely to treat a variety of cancers in patients of all ages. As a result of its extensive use in the clinic and its association with secondary malignancies it has become a compound of great interest with regard to its genotoxic activity in vivo. This paper describes a series of assays that were employed to determine the in vivo genotoxicity of etoposide in a murine model system. The alkaline comet assay detected DNA damage in the bone marrow mononuclear compartment over the dose range of 10--100mg/kg and was associated with a large and dose dependent rise in the proportion of cells with severely damaged DNA. In contrast, the bone marrow micronucleus assay was found to be sensitive to genotoxic damage between the doses of 0.1--1mg/kg without any corresponding increases in cytotoxicity. An increase in the mutant frequency was undetectable at the Hprt locus at administered doses of 1 and 10mg/kg of etoposide, however, an increase in the mutant frequency was seen at the Aprt locus at these doses. We conclude that the BMMN assay is a good short-term predictor of the clastogenicity of etoposide at doses that do not result in cytotoxic activity, giving an indication of potential mutagenic effects. Moreover, the detection of mutants at the Aprt locus gives an indication of the potential of etoposide to cause chromosomal mutations that may lead to secondary malignancy.en
dc.language.isoenen
dc.subject.meshAdenine Phosphoribosyltransferase-
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshComet Assay-
dc.subject.meshDNA Topoisomerases, Type II-
dc.subject.meshEtoposide-
dc.subject.meshHumans-
dc.subject.meshHypoxanthine Phosphoribosyltransferase-
dc.subject.meshIn Situ Hybridization, Fluorescence-
dc.subject.meshMale-
dc.subject.meshMice-
dc.subject.meshMicronucleus Tests-
dc.subject.meshMutagenicity Tests-
dc.subject.meshMutagens-
dc.subject.meshSpleen-
dc.titleAssays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay.en
dc.typeArticleen
dc.contributor.departmentGene Therapy Group, Christie Hospital (NHS) Trust, Wilmslow Road, Manchester M20 4BX, UK. suzanne.turner@bbsrc.ac.uken
dc.identifier.journalMutation Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.